Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

178
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
178
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Australian GP experiences and perspectives of mental health care for adolescents: a qualitative study.

Australian journal of primary health·2026
Same author

Indwelling Pleural Catheter as a Safe and Convenient Alternative to Serial Thoracentesis for the Management of Hepatic Hydrothorax: A Retrospective Propensity-Matched Cohort Study.

Journal of bronchology & interventional pulmonology·2026
Same author

Clinical performance of Magmaris bioresorbable scaffold and modern drug-eluting stents (Biomatrix, Ultimaster, Orsiro) in coronary artery disease: a systematic review and meta-analysis.

Acta cardiologica·2026
Same author

Insights Into Subacute Combined Degeneration of the Cord: 'Rabbit Ear Sign' as a Radiodiagnostic Clue in Case of Vitamin B12 Deficiency Associated With Schizophrenia.

Case reports in neurological medicine·2026
Same author

Detection of mitochondrial bioenergetics using a novel bimodal 3D microelectrode array (MEA)-based biosensor.

Microsystems & nanoengineering·2026
Same author

Long-Term Comparative Outcomes of TNF-α Antagonists vs. Vedolizumab as First-Line Biologic Therapy for Refractory Ulcerative Proctitis: A Propensity-Matched Study.

Biomedicines·2026

Related Experiment Video

Updated: May 23, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.1K

Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S.

Sandra Smieszek1, Bartlomiej Przychodzen1, Christina Tyner1

  • 1Vanda Pharmaceuticals Inc., Washington, DC 20037, USA.

Molecular Therapy. Nucleic Acids
|March 10, 2025
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotides (ASO) show promise for treating Charcot-Marie-Tooth disease type 2S by restoring Immunoglobulin mu-binding protein 2 (IGHMBP2) levels. Preclinical studies demonstrate ASO efficacy and safety in patient cells and animal models.

Keywords:
Charcot-Marie-Tooth Disease type 2SIGHMBP2MT: Oligonucleotides: Therapies and ApplicationsRNA therapeuticsantisense oligonucleotideexon skippinggenetic rescuepersonalized treatmentsplicing variants

More Related Videos

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

6.9K
In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

19.2K

Related Experiment Videos

Last Updated: May 23, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.1K
Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

6.9K
In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

19.2K

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Pathogenic variants in Immunoglobulin mu-binding protein 2 (IGHMBP2) cause alpha-motor neuron degeneration.
  • Charcot-Marie-Tooth disease type 2S (CMT2S) is a rare genetic disorder resulting from IGHMBP2 dysfunction.

Purpose of the Study:

  • To develop and evaluate an antisense oligonucleotide (ASO)-based therapy for CMT2S.
  • To restore functional IGHMBP2 protein levels in patient-derived cells.

Main Methods:

  • Designed a targeted ASO to correct a cryptic intronic splice site variant in IGHMBP2.
  • Treated patient fibroblasts with ASO and assessed IGHMBP2 transcript and protein levels.
  • Analyzed neuromuscular junction (NMJ) function in vitro.
  • Conducted preclinical toxicity studies of the ASO in rats.

Main Results:

  • ASO treatment restored the wild-type IGHMBP2 transcript and increased protein levels by over 50%.
  • ASO therapy rescued NMJ function, reducing fatigue and chaotic tetanus responses in patient cells.
  • Intrathecal ASO administration in rats was well-tolerated over three months.

Conclusions:

  • The developed ASO is a potential therapeutic candidate for CMT2S.
  • N-of-1 ASO therapeutics offer a promising strategy for treating genetically diverse disorders like CMT2S.